Metastatic CRC has been treated with 5‐fluorouracil, which has remained the first choice of chemotherapy drug for many years, and several new targeted drugs such as humanized monoclonal antibody against EGFR (cetuximab) or anti‐VEGFR (bevacizumab) have been recently used for the treatment of CRC patients.3 However, the newly introduced drugs mostly showed very modest benefits at high costs and were often related to drug resistance. This evidence concerns the gene EGFR and colorectal carcinoma.